# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/ 18 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Neocolipor suspension for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances: per dose of 2 ml:
E. coli adhesin F4 (F4ab, F4ac, F4ad), at least … .2.1 SA. U* E. coli adhesin F5, at least……………………… 1.7 SA. U* E. coli adhesin F6, at least ……………………… 1.4 SA. U* E. coli adhesin F41, at least…………………… .1.7 SA. U*
*:
1 SA. U: quantity sufficient to obtain an agglutinating antibody titre of 1 log10 in the guinea pig.
Adjuvant:
Aluminium (as hydroxide)
1.4 mg
Excipients:
Thiomersal
0.2 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
4.
CLINICAL PARTICULARS
4.1 Target species
Pigs (sows and gilts).
4.2 Indications for use specifying the target species
Reduction of neonatal enterotoxicosis of piglets, caused by E. coli strains, expressing the adhesins F4ab, F4ac, F4ad, F5, F6 and F41, during the first days of life.
4.3 Contraindications
None.
4.4 Special warnings
None.
4.5 Special precautions for use
Special precautions for use in animals
- Since the protection of piglets is ensured by colostrum intake, each piglet should ingest a
sufficient quantity of colostrum within 6 hours of birth.
- Vaccinate only healthy animals.
- Do not administer in conjunction with other medicinal products.
2/ 18 Special precautions to be taken by the person administering the veterinary medicinal product to animals
In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.
Wash and disinfect hands after use.
4.6 Adverse reactions (frequency and seriousness)
Vaccination may cause a slight hyperthermia (less than 1.5°C during a maximum period of 24 hours).
4.7 Use during pregnancy, lactation or lay
No special precautions.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the compatibility of this vaccine with any other.
Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated
4.9 Amounts to be administered and administration route
Shake the vial vigorously before use.
Use sterile syringe and needles.
Administer using aseptic procedures.
One 2 ml dose intramuscularly in the neck in the area behind the ear, according to the following schedule:
Primary vaccination:
First injection:
Second injection:
5 to 7 weeks before farrowing 2 weeks before farrowing.
Revaccination:
1 injection 2 weeks before each subsequent farrowing.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No undesirable effects have been observed after the administration of twice the recommended dosage.
4.11 Withdrawal period(s)
Zero days.
5.
IMMUNOLOGICAL PROPERTIES
ATC vet code:
QI09AB02
The vaccine contains the inactivated strains of E. coli expressing the adhesins F4ab, F4ac, F4ad, F5, F6 and F41, which cause neonatal enterotoxicosis in piglets, in aluminium hydroxide adjuvant.
In sows and gilts, the vaccine induces the specific seroconversion of vaccinated animals; piglets are passively immunised by intake of colostrum and milk containing adhesin-specific antibodies.
3/ 18 6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Thiomersal Aluminium hydroxide Sodium chloride
6.2 Incompatibilities
Do not mix with any other vaccine.
6.3 Shelf life
Shelf-life:
18 months at 2 - 8 °C.
Broached vial:
3 hours.
6.4 Special precautions for storage
Store and transport at 2°C - 8°C, protected from light.
Do not freeze.
6.5 Nature and composition of immediate packaging
Box of 5-dose 10 ml vial (glass type I vial with butyl rubber stopper).
Box of 10-dose 20 ml vial (glass type I vial with butyl rubber stopper).
Box of 25-dose 50 ml vial (glass type I vial with butyl rubber stopper).
Box of 50-dose 100 ml vial (glass type I vial with butyl rubber stopper).
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements
7.
MARKETING AUTHORISATION HOLDER
MERIAL 29 avenue Tony Garnier 69007 LYON FRANCE
8.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 98/ 008/ 001-004
9.
DATE OF FIRST RENEWAL OF THE AUTHORISATION
03/ 2008
4/ 18 10 DATE OF REVISION OF THE TEXT
03/ 2008
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
PROHIBITION OF SALE, SUPPLY AND/ OR USE
Not applicable.
5/ 18 ANNEX II
A.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6/ 18 A.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer of the biological active substance
MERIAL Laboratoire de Toulouse 4 Chemin du Calquet 31300 TOULOUSE FRANCE
Manufacturer responsible for batch release
MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F-69800 SAINT PRIEST
FRANCE
Manufacturing authorisation issued by the French Ministère des Affaires Sociales, Ministère délégué à la Santé, and the Ministère de l’ Agriculture et de la Forêt on 31 March 1992.
B.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Veterinary medicinal product subject to prescription.
C.
PROHIBITION OF SALE, SUPPLY AND/ OR USE
Not applicable.
D.
STATEMENT OF THE MRLs WHICH ARE ACCEPTED IN ACCORDANCE WITH COUNCIL REGULATION (EEC) No 2377/ 90
Annex II of Council Regulation (EEC) No 2377/ 90
Pharmacologically substance(s)
active
Animal species
Other provisions
Aluminium hydroxide1
All food producing species
Thiomersal2
All food producing species
For use only as a preservative in multidose vaccines at concentration not exceeding 0.02%
a
Sodium hydroxide3 Sodium chloride4
All food producing species All food producing species
Hydrochloric acid5
All food producing species
For use as excipient
1 OJ No L 290 of 05.12.95 2 OJ No L 110 of 26.04.97 3 OJ No L 272 of 25.10.96 4 OJ No L 290 of 05.12.95 5 OJ No L 143 of 27.06.95
7/ 18 ANNEX III
LABELLING AND PACKAGE INSERT
8/ 18 A.
LABELLING
9/ 18 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Neocolipor suspension for injection
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
per dose of 2 ml:
E. coli adhesin F4 (F4ab, F4ac, F4ad), at least … .2.1 SA. U* E. coli adhesin F5, at least……………………… 1.7 SA. U* E. coli adhesin F6, at least ……………………… 1.4 SA. U* E. coli adhesin F41, at least…………………… .1.7 SA. U* … *:
1 SA. U: quantity sufficient to obtain an agglutinating antibody titre of 1 log10 in the guinea pig.
Adjuvant:
Aluminium (as hydroxide).............................................................................................................
1.4 mg
3.
PHARMACEUTICAL FORM
Suspension for injection
4.
PACKAGE SIZE
5 doses = 10 ml vial.
10 doses = 20 ml vial.
25 doses = 50 ml vial.
50 doses =100 ml vial.
5.
TARGET SPECIES
Pigs (sows and gilts)
6.
INDICATION(S)
Read the package leaflet before use.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular injection
8.
WITHDRAWAL PERIOD
Withdrawal period:
Zero days.
10/ 18 9.
SPECIAL WARNING(S), IF NECESSARY
Shake the vial vigorously prior to use.
10.
EXPIRY DATE
EXP
11.
SPECIAL STORAGE CONDITIONS
Store and transport between 2ºC and 8ºC, protected from light.
Do not freeze.
Shelf-life of broached vial:
3 hours.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Read the package leaflet before use.
13.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MERIAL 29 avenue Tony Garnier F-69007 LYON FRANCE
16.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 98/ 008/ 001 EU/ 2/ 98/ 008/ 002 EU/ 2/ 98/ 008/ 003 EU/ 2/ 98/ 008/ 004
10 ml vial.
20 ml vial.
50 ml vial.
100 ml vial.
17.
MANUFACTURER’ S BATCH NUMBER
Lot
11/ 18 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Neocolipor Suspension for injection Pigs (sows and gilts)
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
adhesins:
F4 (F4ab, F4ac, F4ad), F5, F6, F41 Aluminium adjuvant
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
2 ml = 1 dose 5d 2 ml = 1 dose 10 d 2 ml = 1 dose 25 d
10 ml vial 20 ml vial 50 ml vial
4.
ROUTE(S) OF ADMINISTRATION
Intramuscular injection
5.
WITHDRAWAL PERIOD
6.
BATCH NUMBER
Lot
7.
EXPIRY DATE
EXP {month/ year} >
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
Read the package leaflet before use.
12/ 18 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Neocolipor Suspension for injection Pigs (sows and gilts)
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
per dose of 2 ml: adhesins: * F4 (F4ab, F4ac, F4ad), at least....................................................................................................
2.1 SA. U * F5, at least...................................................................................................................................
1.7 SA. U * F6, at least...................................................................................................................................
1.4 SA. U * F41, at least.................................................................................................................................
1.7 SA. U *:
1 SA. U: quantity sufficient to obtain an agglutinating antibody titre of 1 log10 in the guinea pig.
Adjuvant:
Aluminium (as hydroxide)................................................................................................................
1.4 mg
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
50 dose
100 ml vial
4.
ROUTE(S) OF ADMINISTRATION
Intramuscular injection
5.
WITHDRAWAL PERIOD
6.
BATCH NUMBER
Lot
7.
EXPIRY DATE
EXP {month/ year} >
13/ 18 8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
Shake vigorously prior to use Read the package leaflet before use.
14/ 18 B.
PACKAGE LEAFLET
15/ 18 PACKAGE LEAFLET Neocolipor
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
MARKETING AUTHORISATION HOLDER MERIAL 29 avenue Tony Garnier 69007 LYON FRANCE
MANUFACTURER FOR THE BATCH RELEASE MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F-69800 SAINT PRIEST FRANCE
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Neocolipor suspension for injection
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
per dose of 2 ml:
E. coli adhesin F4 (F4ab, F4ac, F4ad), at least … .2.1 SA. U* E. coli adhesin F5, at least……………………… 1.7 SA. U* E. coli adhesin F6, at least ……………………… 1.4 SA. U* E. coli adhesin F41, at least…………………… .1.7 SA. U* *:
1 SA. U: quantity sufficient to obtain an agglutinating antibody titre of 1 log10 in the guinea pig.
Adjuvant:
Aluminium (as hydroxide).............................................................................................................
1.4 mg
4.
INDICATION(S)
Adjuvanted inactivated vaccine for the reduction of neonatal enterotoxicosis of piglets, caused by E. coli strains, expressing the adhesins F4ab, F4ac, F4ad, F5, F6 and F41.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
Vaccination may cause a slight hyperthermia (less than 1.5°C during a maximum period of 24 hours).
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
16/ 18 7.
TARGET SPECIES
Pigs (sows and gilts)
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
One 2 ml dose according to the following schedule:
Primary vaccination:
First injection:
Second injection:
Revaccination:
5 to 7 weeks before farrowing 2 weeks before farrowing.
1 injection 2 weeks before each subsequent farrowing.
9.
ADVICE ON CORRECT ADMINISTRATION
Intramuscular injection in the neck in the area behind the ear.
Shake the vial vigorously before use.
Use sterile syringe and needles.
Administer using aseptic procedures.
10.
WITHDRAWAL PERIOD
Zero days.
11.
SPECIAL STORAGE PRECAUTIONS
Store and transport at 2°C - 8°C, protected from light.
Do not freeze.
Shelf life of broached vial:
3 hours.
12.
SPECIAL WARNING(S)
- Since the protection of piglets is ensured by colostrum intake, each piglet should ingest a
sufficient quantity of colostrum within 6 hours of birth.
- Vaccinate only healthy animals.
- Do not administer in conjunction with other medicinal products.
No information is available on the compatibility of this vaccine with any other.
Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated
In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.
Wash and disinfect hands after use.
No undesirable effects have been observed after the administration of twice the recommended dosage.
Do not mix with any other vaccine.
17/ 18 13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements
14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
03/ 2008
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
15.
OTHER INFORMATION
The vaccine contains the inactivated strains of E. coli expressing the adhesins F4ab, F4ac, F4ad, F5, F6 and F41, which cause neonatal enterotoxicosis in piglets, in aluminium hydroxide adjuvant.
In sows and gilts, the vaccine induces the specific seroconversion of vaccinated animals; piglets are passively immunised by intake of colostrum and milk containing adhesin-specific antibodies.
Box of 5-dose 10 ml vial (glass type I vial with butyl rubber stopper).
Box of 10-dose 20 ml vial (glass type I vial with butyl rubber stopper).
Box of 25-dose 50 ml vial (glass type I vial with butyl rubber stopper).
Box of 50-dose 100 ml vial (glass type I vial with butyl rubber stopper).
Not all pack sizes may be marketed.
Veterinary medicinal product subject to prescription.
18/ 18